Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }

The stock of one of Canada’s most prominent biotechnology developers, Bellus Health Inc., tanked Monday following disappointing trial results for a drug aimed at treating individuals suffering from a chronic cough.

The Laval, Que., company did report some promising data and committed to continue in its race against several pharmaceutical giants to get similar drugs to market.

“We are very much reassured we have a drug here,” Bellus director Clarissa Desjardins said. “But it’s going to take longer and cost more money … if the data were different, we might be pulling the plug. But that’s not the case. I’d characterize this as a moderate, not insurmountable setback.”

Story continues below advertisement

Stock in Bellus slumped 72 per cent on Monday after reporting its first human trial results for 68 patients. The subjects coughed 10 or more times an hour and had suffered from the cough for more than a year.

The Bellus study results showed its drug, BLU-5937, did not reach its goal of reducing the number of coughs by more than 25 per cent in test subjects in comparison with a placebo. While the drug outperformed the placebo in four different dose sizes, it was not a statistically meaningful improvement, Bellus said. There is no approved treatment for people who suffer from coughs lasting more than eight weeks, which affects an estimated nine million Americans. About 45 per cent of cases are considered moderate to severe.

Regulators haven’t approved a new cough therapy since dextromethorphan – a staple in cold medications – in 1958.

The results are the latest setback for the father and son duo of Francesco and Roberto Bellini in their 18-year quest to build a sequel to the elder Bellini’s HIV/AIDS drug developer BioChem Pharma Inc. Canada’s most successful biotech company, that firm sold to Shire Pharmaceuticals Group PLC for $5.9-billion in 2001.

Bellus, once known as Neurochem Inc., previously failed to develop treatments for Alzheimer’s disease and a rare kidney ailment, spending more than $300-million in the process. Bellus licensed global rights to the cough drug – which pharma giant AstraZeneca had attempted to develop as a pain medication – in 2017, reviving its prospects.

While Bellus CEO Roberto Bellini acknowledged the latest results were disappointing, he said in an interview: “I don’t put this in the failure column. We think there’s benefit for patients here. As we dug in [to the data], we got more and more encouraged.”

The worst sufferers in the study – those who cough more than once every two minutes – did experience a 28 per cent to 32 per cent reduction in coughing while taking the drug. That’s similar to results from recent human trials by pharma giant Shionogi & Co. Ltd.

Story continues below advertisement

The Japanese company, along with Merck & Co., Bayer AG and Bellus are all testing a similar class of drugs that stop a sensory receptor in the upper airway from telling the brain to trigger a cough.

In addition, the Bellus drug was found to be safe for humans, showing no serious adverse side effects, while only two patients experienced partial taste loss. That’s in contrast to Merck’s rival drug, which causes a significant amount of loss in taste among test subjects – a key advantage Bellus is hoping to exploit if both its drugs makes it to market.

“I’m not writing off BLU-5937,” said David Martin, a Bloom Burton & Co. analyst, after cutting his rating on Bellus to Hold from Buy and slashing his stock price target to US$5 from US$14. He said the company still has a chance to generate results that show its drug can compete. “It’s just going to take at least one more trial to get us there.”

Bellus is planning a follow-on study later this year on 250 patients to further explore the drug’s effectiveness among those that responded best in the first study. That trial is expected to cost US$20-million. Bellus had US$78-million in cash and short term investments at the end of March.

Francesco Bellini, the chairman of Bellus, reiterated his optimism despite Monday’s setback. “The first thing I did this morning was I bought 100,000 shares,” he said in an interview. “I don’t understand why experienced people, expert analysts or investors don’t see the same [opportunity] like I see … I see now a good opportunity to buy a lot of shares at a very cheap price.”

Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.

Follow related topics

Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies